We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+16.88%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.03B
AUM Growth
-$287M
(-22%)
Cap. Flow
-$398M
Cap. Flow
% of AUM
-38.68%
Top 10 Holdings %
Top 10 Hldgs %
14.04%
Holding
1,478
New
335
Increased
269
Reduced
346
Closed
503
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$12.3M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$10.9M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$10.4M |
| 4 |
Tesla
TSLA
|
+$9.96M |
| 5 |
NVIDIA
NVDA
|
+$8.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.4M |
| 2 |
Broadcom
AVGO
|
+$9.33M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$8.68M |
| 4 |
DESP
Despegar.com
DESP
|
+$7.15M |
| 5 |
Oracle
ORCL
|
+$6.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.86% |
| 2 | Consumer Discretionary | 12.74% |
| 3 | Healthcare | 12.34% |
| 4 | Communication Services | 10.34% |
| 5 | Industrials | 8.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Sprinklr
CXM
$1.61B
| $89.7K | 0.01% |
+10,600
| New | +$84.9K |
|
927
Designer Brands
DBI
$333M
| $88.1K | 0.01% |
37,000
-423
| -1% | -$1.28K |
|
|
VISN
928
Vistance Networks Inc
VISN
$2.52B
| $87.8K | 0.01% |
10,605
-18,588
| -64% | -$97.3K |
|
929
Rayonier Advanced Materials
RYAM
$610M
| $84.6K | 0.01% |
+21,984
| New | +$92.3K |
|
930
CS Disco
LAW
$279M
| $84.3K | 0.01% |
+19,300
| New | +$75.6K |
|
931
Conduent
CNDT
$264M
| $84.2K | 0.01% |
31,886
-63,364
| -67% | -$149K |
|
|
KGEI
932
Kolibri Global Energy
KGEI
$181M
| $83.4K | 0.01% |
+12,175
| New | +$83.7K |
|
933
Protalix BioTherapeutics
PLX
$198M
| $83K | 0.01% |
+56,055
| New | +$115K |
|
934
Arvinas
ARVN
$572M
| $81.3K | 0.01% |
11,045
-52,695
| -83% | -$388K |
|
935
Arbutus Biopharma
ABUS
$915M
| $78.2K | 0.01% |
+25,318
| New | +$84.1K |
|
936
4D Molecular Therapeutics
FDMT
$562M
| $76.8K | 0.01% |
20,700
-1,800
| -8% | -$6.33K |
|
937
Clarus
CLAR
$143M
| $73.6K | 0.01% |
21,200
+2,800
| +15% | +$9.48K |
|
|
ATYR
938
aTyr Pharma
ATYR
$50.1M
| $73.4K | 0.01% |
14,481
-6,837
| -32% | -$26.9K |
|
939
Green Plains
GPRE
$1.03B
| $72.5K | 0.01% |
12,023
-8,553
| -42% | -$37.7K |
|
940
Xeris Biopharma Holdings
XERS
$1.45B
| $72.4K | 0.01% |
+15,500
| New | +$71K |
|
|
NEWP
941
New Pacific Metals
NEWP
$1.17B
| $72.3K | 0.01% |
53,948
-85,952
| -61% | -$109K |
|
|
CMRC
942
Commerce.com Inc Series 1
CMRC
$184M
| $71.5K | 0.01% |
+14,300
| New | +$73.7K |
|
943
Granite Ridge Resources
GRNT
$644M
| $70.1K | 0.01% |
+11,000
| New | +$60.6K |
|
944
Protara Therapeutics
TARA
$232M
| $69.1K | 0.01% |
+22,816
| New | +$78.7K |
|
|
ONTF
945
DELISTED
ON24
ONTF
| $69K | 0.01% |
+12,700
| New | +$65.1K |
|
946
Stereotaxis
STXS
$141M
| $67.7K | 0.01% |
31,943
-10,016
| -24% | -$20.4K |
|
947
Resources Connection
RGP
$145M
| $67K | 0.01% |
12,475
+1,375
| +12% | +$7.46K |
|
948
The RealReal
REAL
$1.5B
| $64.9K | 0.01% |
+13,552
| New | +$74.6K |
|
949
Gain Therapeutics
GANX
$77.6M
| $64.5K | 0.01% |
35,820
| – | – |
|
950
The Honest Company
HNST
$586M
| $62.5K | 0.01% |
+12,281
| New | +$58.9K |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Prelude Capital Management held 1,478 positions worth $1.03B, down 22% from $1.32B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Prelude Capital Management withdrew a net $398M in Q2 2025, closing 503 positions and reducing 346 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Prelude Capital Management opened a new position in Alphabet (Google) Class C worth $11.7M.
- Prelude Capital Management's largest Q2 2025 buy was Alphabet (Google) Class C: 65,723 shares worth $11.7M.
- Prelude Capital Management added most to Meta Platforms (Facebook) in Q2 2025, an estimated $12.3M increase.
- Prelude Capital Management's biggest Q2 2025 reduction was Broadcom, cutting an estimated $9.33M.
- Prelude Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $10.4M.
- Prelude Capital Management's ten largest holdings make up 14% of its $1.03B portfolio in Q2 2025.
- Prelude Capital Management opened 335 new positions and closed 503 in Q2 2025.
- Prelude Capital Management's portfolio value fell 22% quarter-over-quarter to $1.03B.
Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.